ROVI informs on the evaluation process to obtain marketing authorisation for Risvan®

Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of schizophrenia in adults


ROVI informs on the evaluation process to obtain marketing authorisation for Risvan®

  • The United States Food and Drug Administration (FDA) has issued a Complete Response Letter. In this letter, the FDA informs ROVI that it considers the responses to the evaluation of the Risvan® dossier to be complete and makes no additional observations.
  • The letter states that ROVI must close the observations made by the FDA during its inspection in May 2023. ROVI will submit a response to reinitiate the procedure providing details of the responses that have already been filed. ROVI will then await a further notification from the FDA with the estimated User Fee Goal Date for the closure of the procedure, which is expected to be in February 2024.
  • There are no observations that have not yet been resolved by ROVI’s suppliers.
Average: 3.7 (3 votes)
 
Related
  Madrid, 10 July 2025. Laboratorios Farmacéuticos ROVI, S.A. (“ROVI”) announces that, on 9 July 2025, the Technological...
4 min
10/07/2025
ROVI continues with its shareholder remuneration policy after completing the third consecutive share buyback programme last year and...
5 min
18/06/2025
  Madrid, 8 May 2025.- Laboratorios Farmacéuticos ROVI, S.A. (“ROVI”) announces that, on 7 May 2025, the Technological Development...
4 min
08/05/2025